NCT01492088 (Clinical Trial/ Brentuximab vedotin)

Study Title
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma (NCT01492088)

Trial Description
This is a phase I/II, open-label, single-agent, multi-center, dose-escalation study of brentuximab vedotin in pediatric patients with relapsed or refractory systemic anaplastic large-cell lymphoma (sALCL) or Hodgkin lymphoma (HL)

This trial is sponsored by Millennium Pharmaceuticals, Inc [1]

Study data

  • Condition: Lymphoma
  • Interventions:
  • Phase: I & II
  • Estimated Enrollment: 42
  • Start: April 2012
  • Estimated Completion: January 2017
  • Last verified: February 2015

Study Schematic

NCT01492088


Last Editorial review: July 6, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.